Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Blood Test to Provide Safe, Early Prenatal Genetic Screening

By LabMedica International staff writers
Posted on 08 Apr 2014
A noninvasive blood test has been developed to enable safe early prenatal detection of fetal chromosome abnormalities such as in Down's syndrome as well as the more challenging detection of microdeletions.

Synapse Diagnostics (Hyderabad, India) now offers "Materni T21 PLUS", a highly accurate prenatal genetic blood test for specific chromosome conditions associated with birth defects. More...
Conducted on blood collected from the mother as early as 10 weeks of pregnancy, genetic abnormalities in the fetus, such as Down's Syndrome and multiple other defects, can be detected early using accurate, cutting-edge technology – a state-of-the-art genomic DNA sequencing based test – providing a clear and precise result which can be easily interpreted. Materni T21 PLUS is the only test in the international market that detects not only abnormalities such as in Down's syndrome but also microdeletion type defects. Microdeletion type abnormalities are difficult to detect, such that parents and clinicians usually spend years after birth trying to diagnose them as underlying the child's symptoms. With this advanced test they can be detected early in pregnancy.

Dr. Samit Sekhar, Managing Director for Synapse Diagnostics India, commented, “Down’s syndrome is a naturally occurring chromosomal arrangement that has always been a part of the human condition, being universally present across racial, gender, or socioeconomic lines, and affecting approximately 1 in 800 live births, although there is considerable variation worldwide. Down's syndrome usually causes varying degrees of intellectual and physical disability in the baby and is associated with various other medical issues.”

The current, amniocentesis, test is not only performed late in pregnancy but is also invasive with a risk of miscarriage. Furthermore, in some cases it cannot definitively pick up the microdeletions. Materni T21 provides a noninvasive alternative for early screening that is safe for both mother and unborn child. With this technology doctors and parents can safely obtain accurate information very early, which also helps mitigate anxiety associated with more aggressive procedures or with the uncertainty of other blood tests that may give only probability-based results.

The Materni T21 Plus test is developed and validated by Sequenom Center for Molecular Medicine (Sequenom CMM), a CAP-accredited and CLIA-certified molecular diagnostics laboratory based in San Diego (CA, USA).

Related Links:

Synapse Diagnostics



New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.